Log In
Print
BCIQ
Print
Print this Print this
 

SAR245408, XL147

  Manage Alerts
Collapse Summary General Information
Company Exelixis Inc.
DescriptionOral selective inhibitor of phosphoinositide 3-kinase (PI3K)
Molecular Target Phosphoinositide 3-kinase (PI3K)
Mechanism of ActionPhosphoinositide 3-kinase (PI3K) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today